.

Deeper Knowledge, Faster

  • Anticipate your formulary budget
  • Analyze global market entry opportunities
  • Find suppliers and generic API sources

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Boehringer Ingelheim
Farmers Insurance
Mallinckrodt
Dow
Moodys
Harvard Business School
Express Scripts
UBS
McKesson
Teva

Generated: June 22, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021526

« Back to Dashboard
NDA 021526 describes RANEXA, which is a drug marketed by Gilead and is included in one NDA. It is available from four suppliers. There are ten patents protecting this drug. Additional details are available on the RANEXA profile page.

The generic ingredient in RANEXA is ranolazine. There are fifteen drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the ranolazine profile page.

Summary for NDA: 021526

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details

Suppliers and Packaging for NDA: 021526

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
RANEXA
ranolazine
TABLET, EXTENDED RELEASE;ORAL 021526 NDA Aphena Pharma Solutions - Tennessee, LLC 43353-880 43353-880-83 3600 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (43353-880-83)
RANEXA
ranolazine
TABLET, EXTENDED RELEASE;ORAL 021526 NDA Cardinal Health 55154-4427 55154-4427-0 10 POUCH in 1 BAG (55154-4427-0) > 1 TABLET, FILM COATED, EXTENDED RELEASE in 1 POUCH (55154-4427-6)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength1GM
Approval Date:Feb 12, 2007TE:RLD:Yes
Patent:6,369,062Patent Expiration:May 27, 2019Product Flag?YSubstance Flag?Delist Request?Y
Patent:6,503,911Patent Expiration:May 27, 2019Product Flag?YSubstance Flag?Delist Request?
Patent:6,617,328Patent Expiration:May 27, 2019Product Flag?YSubstance Flag?Delist Request?

Expired Orange Book Patents for NDA: 021526

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Gilead
RANEXA
ranolazine
TABLET, EXTENDED RELEASE;ORAL021526-001Feb 12, 20074,567,264► Subscribe
Gilead
RANEXA
ranolazine
TABLET, EXTENDED RELEASE;ORAL021526-002Jan 27, 20064,567,264► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Teva
Fuji
Baxter
Express Scripts
Queensland Health
Fish and Richardson
Farmers Insurance
AstraZeneca
McKesson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot